Last updated: May 11, 2026
TRANXENE (clorazepate; benzodiazepine) has no recent, high-significance “late-stage” development program in the public domain under the brand name, and market supply largely tracks generic availability for clorazepate. The business-relevant risk profile is therefore driven by (1) how long the remaining brand-specific IP and any regulatory exclusivities extend in key markets, (2) whether new clorazepate formulations or use patents exist that can slow generic entry, and (3) reimbursement and dispensing substitution dynamics for older benzodiazepines.
What is TRANXENE (clorazepate) and what is its current FDA regulatory status?
Featured snippet: TRANXENE is an FDA-approved brand of clorazepate (benzodiazepine). Current market access is dominated by generics, and brand-market share is constrained by patent and exclusivity timelines tied to clorazepate rather than to a newer platform.
Is TRANXENE currently FDA-listed in the Orange Book?
A brand’s practical exclusivity and generic entry risk is assessed via the FDA Orange Book (active ingredient, dosage form, patent listings, and patent expiry). This update requires an Orange Book status pull for TRANXENE-specific listings, including formulation and method-of-use patents, and any “exclusivity” blocks (e.g., new chemical entity, new clinical investigation, pediatric exclusivity). No such Orange Book listing data is present in the provided inputs.
What FDA approval pathway applies to TRANXENE?
Clorazepate is an older benzodiazepine. For the purpose of generic entry risk, it typically sits in a post-approval era where generic manufacturers reference established approvals under ANDA frameworks. The controlling item becomes patent and exclusivity, not a development pathway.
What are the main dosage forms and strengths from a competitive risk standpoint?
Market share is heavily segmented by oral formulation and strength (tablets/capsules/liquid, where applicable). Patent coverage can be dosage-form-specific (formulation process or specific strengths). No TRANXENE dosage/strength listing table is possible from the provided inputs.
What clinical trials exist for TRANXENE, and what is the latest update?
Featured snippet: Public clinical trial visibility for TRANXENE under that brand is limited; most “trial” activity in the clorazepate class is historical or bundled under generic clorazepate rather than the brand label.
What to look for in clinical trial updates
For a business decision, the signal is late-stage activity (Phase 3 or pivotal Phase 2 programs) and whether new indications, new formulations, or new delivery systems are being pursued. Without an identified recent trial record, the clinical-trials update is that the active competitive threat is not a new brand study but ongoing generic competition.
How should trial activity translate into near-term market expectations?
When there is no new late-stage program, projected growth is primarily a function of:
- generic substitution rates,
- payer coverage stability for benzodiazepines,
- controlled-substance scheduling enforcement and prescribing behavior,
- label and safety communications affecting benzodiazepine use.
What would a late-stage update change for exclusivity?
New clinical investigations can create exclusivity only if they support a supplemental approval that triggers exclusivity eligibility. Without a new supplemental application or identifiable study milestones, the exclusivity engine is not activated.
When does clorazepate or TRANXENE lose exclusivity, and what patents block generics?
Featured snippet: For older benzodiazepines, the principal entry barriers are typically expiring decades-old brand patents and any last-standing formulation or method-of-use patents. Specific expiry dates require Orange Book patent listing data and patent-grant/patent-application histories for the brand owner.
How many patents protect TRANXENE in key markets?
A defensible answer must enumerate:
- Orange Book patents by type (composition, formulation, method of use, manufacturing),
- jurisdictions (US, EU, UK, CA, etc.),
- and each patent’s expiration and any terminal disclaimers.
No patent list or expiry table is provided in the inputs, so a complete protected-rights map cannot be produced.
What is the likely patent strategy for older benzodiazepines?
For legacy products like clorazepate:
- Composition-of-matter patents generally expired long ago.
- Residual barriers usually come from formulation, manufacturing process, or specific dosing regimens.
- Generic entry is often governed by whether any listed patents remain unexpired for each dosage form/strength.
What patent expiration dates matter for an ANDA entry?
The material schedule is:
- earliest expiring listed formulation/manufacturing patents,
- earliest expiring method-of-use patents (if any),
- and any pediatric exclusivity extensions (if applicable).
No such schedule is available without Orange Book listing extraction.
How many ANDA Paragraph IV challenges exist for TRANXENE, and what litigation outcomes matter?
Featured snippet: Generic entry into older benzodiazepines commonly occurs via ANDAs with either paragraph IV certifications (when a listed patent is asserted) or paragraph III (if patents are expired). Whether paragraph IV exists and the number of challenges requires Orange Book ANDA litigation dockets and ANDA notices, plus settlement details if filed.
What patent-litigation signals should be prioritized
For each Orange Book-listed patent:
- ANDA filer identity
- paragraph IV filing date
- 30-month stay trigger
- court decision date (infringement or invalidity)
- any settlement with launch “carve-out” dates
No docket data is provided in the inputs, so a “how many” and “who” answer cannot be generated without fabricating facts.
What is the market size and growth outlook for TRANXENE (clorazepate) over the next 3–5 years?
Featured snippet: The near-term outlook for TRANXENE is constrained by generic penetration. The realistic growth driver is not new brand development but stabilization or decline rates relative to substitution pressure.
Market model framework used for projection
A defensible projection requires baseline:
- US brand sales (and/or channel data),
- total clorazepate market volume,
- generic share and pricing trends,
- payer mix and utilization changes.
No sales or pricing dataset is present in the inputs, so a quantified 3–5 year forecast cannot be produced.
What typically drives demand for benzodiazepines in the US
- prescribing volume trend and guideline alignment,
- safety communications and risk management,
- controlled-substance policy changes that affect schedules and refills,
- substitution from alternative benzodiazepines or non-benzodiazepine anxiolytics.
How to interpret “projection” when branded supply is thin
For older controlled-substance products, the brand can become a small fraction of total ingredient market. A projection should therefore be framed as:
- ingredient-level volume outlook,
- then brand share likelihood.
No ingredient-level volume data is provided in the inputs.
Which companies compete with TRANXENE clorazepate, and how does their product mix affect pricing and volume?
Featured snippet: Competition is predominantly generic clorazepate manufacturers, with pricing discipline determined by supply, settlement-driven entry timing, and any remaining unexpired patents per dosage form/strength.
What is required to map the competitor set
A complete competitor analysis needs:
- NDC-level listings for clorazepate,
- manufacturer identities from FDA Orange Book,
- label and strength segmentation,
- and historical launch dates.
No Orange Book NDC-level extract is available in the inputs.
What formulation and method-of-use patents could matter for TRANXENE?
Featured snippet: If any patents remain, they are most likely tied to formulation (composition/process) or specific clinical use regimens that can support a method-of-use claim.
Common patent categories that slow generics
- film coating or excipient systems tied to release characteristics,
- manufacturing process parameters that affect bioavailability,
- dose titration regimens,
- specific anxiety indications or patient populations.
No identified patent numbers are present in the inputs.
What are the biosimilar or biologic risks for TRANXENE?
Featured snippet: TRANXENE is a small-molecule benzodiazepine and is not a biologic; biosimilar risk does not apply.
How does TRANXENE compare with other benzodiazepines on market and IP?
Featured snippet: Competitive substitution tends to favor older generics with comparable dosing convenience and payer familiarity; clorazepate competes within the broad benzodiazepine class.
What drives relative positioning
- dosing schedule,
- tablet size and excipient tolerability,
- prescriber and patient familiarity,
- controlled-substance prescribing constraints.
No cross-drug pricing or utilization datasets are available in the inputs to support a quantified comparison.
Key patent and exclusivity decision points for licensing or litigation involving TRANXENE
Featured snippet: For legacy benzodiazepines, licensing and litigation value is usually in the last remaining formulation or method-of-use patents for a specific strength or dosage form, not in broad composition-of-matter estates.
Licensing leverage
- Identify remaining Orange Book-listed patents per NDC and earliest expiration.
- Confirm whether any ANDA paragraph IV filings exist tied to those patents.
- Use 30-month stay and settlement launch dates to model “blocked” versus “design-around” entry.
Litigation risk
- Most court outcomes for older controlled-substance drugs hinge on routine validity and obviousness arguments.
- Settlement risk is often higher when patents are narrow (formulation/process) and design-arounds are plausible.
No patent data is provided to evaluate these points for TRANXENE.
Key Takeaways
- TRANXENE (clorazepate) is an established benzodiazepine where near-term business outcomes are driven primarily by generic substitution and residual patent/exclusivity timelines.
- A complete clinical trials update with recency and Phase/endpoint detail cannot be supported from the provided inputs.
- A complete IP and generic-entry map (Orange Book status, patent expiry dates, ANDA paragraph IV counts, and litigation/settlement dates) cannot be generated without Orange Book and docket data.
- Biosimilar risk does not apply because TRANXENE is not a biologic.
FAQs
- How do I check Orange Book patent listings for TRANXENE clorazepate by NDC and strength?
- What is the typical generic entry sequence for older benzodiazepines: paragraph III vs paragraph IV?
- Which patent types (formulation, manufacturing, method-of-use) are most likely to remain active for legacy small molecules?
- How do controlled-substance scheduling and safety communications affect benzodiazepine prescription volumes and brand share?
- What settlement-date signals matter most for forecasting generic launches of clorazepate products?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026).
- FDA Drug Trials Snapshots (Clorazepate/TRANXENE searches). (Accessed 2026).
- FDA Purple Book: Drug Safety and Availability. (Accessed 2026).
- FDA ANDA Patent Certifications and 30-month stay framework (Orange Book / 21 U.S.C. § 355). (Accessed 2026).
